Genentech Avastin Supply Will Come From Two Sites; BLA Coming Soon
Executive Summary
Commercial supply for Genentech's vascular endothelial growth factor inhibitor Avastin could come from two manufacturing facilities, Chief Medical Officer Susan Hellmann, MD, said during an investor conference call July 9
You may also be interested in...
Genentech To Submit Avastin sBLA For Vacaville Facility In First Half 2004
Genentech will submit an sBLA for a back-up manufacturing site for the oncologic Avastin during the first half of 2004
Genentech To Submit Avastin sBLA For Vacaville Facility In First Half 2004
Genentech will submit an sBLA for a back-up manufacturing site for the oncologic Avastin during the first half of 2004
Roche Will Challenge Amgen In U.S. EPO Market; Oncology Business Growing
Roche expects to enter the U.S. EPO market with the continuous erythropoetin receptor activator R-744, Global Pharmaceuticals Head William Burns told securities analysts during a July 23 meeting in Zurich